Baclofen Dosing Recommendations
Start baclofen at 5 mg three times daily (15 mg/day total) and increase by 5 mg per dose every 3 days, with a standard maximum of 80 mg/day (20 mg four times daily), though elderly and renally impaired patients require substantially lower starting doses and more cautious titration. 1
Standard Dosing Protocol
The FDA-approved titration schedule follows a structured 12-day escalation 1:
- Days 1-3: 5 mg three times daily (15 mg/day)
- Days 4-6: 10 mg three times daily (30 mg/day)
- Days 7-9: 15 mg three times daily (45 mg/day)
- Days 10-12: 20 mg three times daily (60 mg/day)
- Beyond day 12: Further increases may continue to maximum 80 mg/day (20 mg four times daily)
The optimal dose typically falls between 40-80 mg daily. Use the lowest dose that achieves therapeutic benefit 1.
Critical Adjustments for Special Populations
Elderly Patients
In older adults, start at 100-200 mg/day of gabapentin-equivalent dosing principles, which translates to even lower baclofen starting doses than standard—consider 5 mg once or twice daily initially. 2 Elderly patients show poor tolerability to baclofen, with unacceptably high rates of drowsiness even at standard doses 3. One study was discontinued specifically because elderly stroke patients experienced excessive sedation 3. The pharmacokinetics differ in elderly patients: they take longer to reach peak plasma concentrations, though peak values may be lower 3.
Renal Impairment
Baclofen requires aggressive dose reduction in any degree of renal impairment because it is primarily renally cleared and accumulates rapidly, causing severe neurotoxicity. 1, 4 This is a critical safety issue frequently overlooked in practice.
Key considerations for renal dosing:
- Moderate renal impairment (CrCl 30-60 mL/min): Start at 5 mg once daily
- Severe renal impairment (CrCl <30 mL/min): Consider avoiding baclofen entirely or use 5 mg every other day with close monitoring
- Dialysis patients: Toxicity reported at doses as low as 5-20 mg/day (mean 20 mg/day) 4
Baclofen toxicity in renal patients presents with CNS depression, seizures, and encephalopathy, typically 2-3 days after initiation but sometimes up to 16 weeks later 4. Recovery requires 2 hours to 8 days depending on whether hemodialysis is used 4.
Maximum Dosing Considerations
While the FDA maximum is 80 mg/day 1, research literature describes use up to 630 mg/day for alcohol use disorders 5. However, high-dose baclofen (>100 mg/day) carries substantially increased risk of serious adverse events without proven efficacy benefit. A rigorous 2016 RCT found no difference between high-dose (mean 93.6 mg, up to 150 mg), low-dose (30 mg), and placebo for alcohol dependence 6. Doses above 300 mg/day are associated with severe CNS depression, seizures (36% of cases), and respiratory depression requiring mechanical ventilation (54.5% of toxicity cases) 7.
Drug Interactions Requiring Dose Modification
The combination of baclofen with pregabalin produces synergistic CNS depression even at therapeutic doses, particularly in patients with any renal impairment. 8 A 2025 case report documented complete CNS depression and coma in a patient with only mild renal impairment (eGFR 77 mL/min) taking baclofen 30 mg/day plus pregabalin 300 mg/day 8. When combining these agents, reduce both starting doses by at least 50%.
Discontinuation Protocol
Never abruptly discontinue baclofen—taper slowly over at least 1-2 weeks to prevent withdrawal seizures and hallucinations. 1 Baclofen withdrawal manifests with severe psychiatric disturbances (up to 20.6% of cases), delirium, agitation, and autonomic instability, typically within 1-4 days of abrupt cessation 7. Rapid baclofen reinitiation consistently resolves withdrawal symptoms 7.
Common Pitfalls to Avoid
Prescribing standard doses in unrecognized renal impairment: Always calculate CrCl before initiating baclofen, as normal serum creatinine does not exclude significant renal dysfunction in elderly patients 9
Continuing escalation beyond 80 mg/day for spasticity: Higher doses lack evidence for improved efficacy and dramatically increase toxicity risk 6, 7
Combining with other GABAergic agents without dose reduction: Particularly dangerous with pregabalin, benzodiazepines, or gabapentin 8
Using in stroke patients: Baclofen has not shown benefit in stroke-related spasticity and these patients demonstrate particularly poor tolerability 1